{
  "name" : "dacemirror.sci-hub.se_journal-article_8bd249e39ed8e147f9d4fd724cd4ba06_sun2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Boron Dipyrromethene Nano-Photosensitizers for Anticancer Phototherapies",
    "authors" : [ "Wen Sun", "Xueze Zhao", "Jiangli Fan", "Jianjun Du", "Xiaojun Peng" ],
    "emails" : [ "fanjl@dlut.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "1804927 (1 of 25) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nreview www.small-journal.com"
    }, {
      "heading" : "Boron Dipyrromethene Nano-Photosensitizers",
      "text" : "for Anticancer Phototherapies"
    }, {
      "heading" : "Wen Sun, Xueze Zhao, Jiangli Fan,* Jianjun Du, and Xiaojun Peng",
      "text" : "Dr. W. Sun, X. Zhao, Prof. J. Fan, Dr. J. Du, Prof. X. Peng State Key Laboratory of Fine Chemicals Dalian University of Technology 2 Linggong Road, Hi-tech Zone, Dalian 116024, China E-mail: fanjl@dlut.edu.cn Dr. W. Sun, X. Zhao, Prof. J. Fan, Dr. J. Du, Prof. X. Peng Research Institute of Dalian University of Technology in Shenzhen Gaoxin South Fourth Road, Nanshan District, Shenzhen 518057, China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/smll.201804927.\nDOI: 10.1002/smll.201804927\nPDT is based on the electron or energy interactions between PSs in triplet states and oxygen (O2) or nearby substrates under light irradiation, generating ROS, such as free radicals (type I) and singlet oxygen (1O2) (type II).[18–23] When certain PSs specifically localize in tumor sites via systemic administration and are then activated by light with a specific wavelength, a series of photochemical reactions are initiated and generate ROS to inhibit tumor growth.[22,24,25]\nPTT is also a commonly used type of phototherapy for cancer treatment.[26–30] Typically, PSs generate heat through nonradiative relaxation pathways from excited states to the ground state by absorbing photons produced by light irradiation, eventually leading to cancer cell death.[31–33] Additionally, PTT requires PSs that exhibit low fluorescence and 1O2 quantum yield to ensure a high nonradiative relaxation probability.[34–36]\nA number of dye sensitizers, including porphyrin, phthalocyanine, and cyanine, have been assessed for cancer treatment using PDT and/or PTT.[37–42] Boron dipyrromethene (BODIPY) has attracted much interest with respect to cancer phototherapy because it possesses unique chemical and physical properties: intense absorption at relatively long wavelength, long triplet excited state lifetime, and excellent photostability.[43,44] In addition, BODIPY synthesis and modification are facile and readily controllable.[12,45] Moreover, BODIPY-containing nanoparticles as nano-photosensitizers were constructed by polymer encapsulation, dye precipitation, or host–guest interactions. In contrast to traditional low- molecular-weight BODIPY photosensitizers, these nano- photosensitizers are promising for in vivo applications, as they exhibit enhanced water solubility and biocompatibility via proper surface modifications, and more efficient tumor accumulation via enhanced permeability and retention (EPR) effects.[46–50] These characteristics of the nano-photosensitizers eventually improve their phototherapeutic efficiency with tumors and reduce their toxic side effects in healthy tissues.\nThis review focuses on design and preparation of BODIPYcontaining nano-photosensitizers for anticancer phototherapy. The review contains three sections: BODIPY nanoparticles (NPs) for PDT, PTT, and the combination of PDT and PTT for anticancer treatment. In each section, the design strategies, working principles, and detailed in vitro and in vivo applications are reviewed. The future development and remaining challenges in this field are also discussed.\nAs traditional phototherapy agents, boron dipyrromethene (BODIPY) photosensitizers have attracted increasing attention due to their high molar extinction coefficients, high phototherapy efficacy, and excellent photostability. After being formed into nanostructures, BODIPY-containing nano-photosensitizers show enhanced water solubility and biocompatibility as well as efficient tumor accumulation compared to BODIPY molecules. Hence, BODIPY nano-photosensitizers demonstrate a promising potential for fighting cancer. This review contains three sections, classifying photodynamic therapy (PDT), photothermal therapy (PTT), and the combination of PDT and PTT based on BODIPY nano-photosensitizers. It summarizes various BODIPY nanophotosensitizers, which are prepared via different approaches including molecular precipitation, supramolecular interactions, and polymer encapsulation. In each section, the design strategies and working principles of these BODIPY nano-photosensitizers are highlighted. In addition, the detailed in vitro and in vivo applications of these recently developed nano-photosensitizers are discussed together with future challenges in this field, highlighting the potential of these promising nanoagents for new tumor phototherapies."
    }, {
      "heading" : "Photodynamic Therapy",
      "text" : ""
    }, {
      "heading" : "1. Introduction",
      "text" : "Cancer has been plaguing human lives for centuries and causes millions of deaths annually.[1,2] Although surgery, chemotherapy, and radiotherapy are widely used forms of cancer therapy, these traditional treatments are severely limited by poor efficiency and serious side effects.[2–5] As a burgeoning cancer tool, phototherapy offers specific spatiotemporal selectivity and minimal invasion into healthy tissues.[6–10] Phototherapy generally involves the activation of photosensitizers (PSs) under light irradiation to induce cancer cell phototoxicity by generating reactive oxygen species (ROS) (photodynamic therapy, PDT) or heating via nonradiative relaxation pathways (photothermal therapy, PTT).[11–17]\nSmall 2019, 1804927\n1804927 (2 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com"
    }, {
      "heading" : "2. BODIPY Nano-Photosensitizers for PDT",
      "text" : "In PDT, PSs with sensitivity to red or near-infrared (NIR) light in the “650–900 nm” therapeutic window have received increasing attention because they allow deeper tissue penetration than those with sensitivity to ultraviolet (UV) or shortwavelength visible (VIS) light.[19,51–55] PSs with long triplet lifetimes are also desired to ensure high ROS production yields. Additionally, good photostability is essential for ROS production yield, which eventually influences the therapeutic efficacy.\nBODIPY-containing nano-photosensitizers demonstrate excellent photostability and biocompatibility. In addition, by facile modification BODIPY with conjugated structures and heavy atoms, the absorption wavelength of BODIPY nano- photosensitizers could reach red or even NIR region, making these nano-photosensitizers suitable for deep-tissue phototherapy.[56] In addition, the high ROS production yield resulting from the long triplet lifetime (1–200 µs) of BODIPY PSs can cause severe toxicity to tumor cells.[57] Thus, BODIPYcontaining nano-photosensitizers have recently been widely studied and used in PDT."
    }, {
      "heading" : "2.1. BODIPY Nano-Photosensitizers from Small Molecule Self-Assembly",
      "text" : "BODIPY is a hydrophobic organic compound with a rigid structure, and its limited water solubility hinders biological use.[58] The linking of amphiphilic molecules by linking hydrophobic BODIPY with hydrophilic chains, such as polyethylene glycol (PEG), can result in the formation of NPs via self-assembly.[59] In a pioneering work, Ruan and co-workers used amphiphilic BODIPY to obtain nano-photosensitizers (Figure 1a).[60] BDPBr2, activated by red light, was synthesized, which generated 1O2 with high efficiency (76%, λex = 660 nm) due to the heavy atom effect. In fact, heavy atoms including bromine and iodine can accelerate the transformation of PSs from singletto-triplet states of PSs and enhance the probability of energy transfer between photosensitizers and O2. The PEG chain attached to BDPBr2 improved water solubility and encapsulated BDPBr2 after nanoparticle formation. The mean nanoparticle size was ≈100 nm, which allowed longer circulation and retention than those of free molecules via the EPR effect (Figure 1b). Cell viability remained at ≈30% after incubation with the nano-photosensitizer (0.005 mg mL−1 BDPBr2) with 660 nm laser irradiation (10 mW cm−2, 10 min). Conversely, negligible cell toxicity was detected in the dark, indicating that the NPs had good biocompatibility. After the intravenous injection of newly synthesized nano-photosensitizers in vivo, tumors were significantly inhibited under 660 nm laser irradiation (35 mW cm−2 for 20 min) irradiation (Figure 1c).\nIn another study, Zhang et al. described a three-armed distyryl-BODIPY conjugated with mannoses as the tumortargeting moieties (Figure 2a).[61] The amphiphilic molecules spontaneously assembled into NPs (BODIPY with mannosenanomicelles (BTM-NMs), roughly spherical in shape) in an aqueous solution of Tween 80 (Figure 2b). No significant change in size was observed when the BODIPY with\nWen Sun received his Ph.D. degree in 2017 from MaxPlanck-Institute for Polymer Research, Germany. He joined Dalian University of Technology as an Associate Professor of State Key Laboratory of Fine Chemicals from 2018. His research interests focus on the construction of photoresponsive materials for bioimaging, diagnosis and anticancer phototherapies.\nXueze Zhao received his B.E. degree in Dalian University of Technology in 2016. Now, he is a Ph.D. candidate under the supervision of Prof. Jiangli Fan in State Key Laboratory of Fine Chemicals, Dalian University of Technology. Currently, his research interests mainly focus on exploiting functional photosensitizers for photodynamic therapy.\nJiangli Fan received her Ph.D. from Dalian University of Technology in 2005. In 2010, she attended the University of South Carolina (USA) as a visiting scholar. She is currently a Professor at the State Key Laboratory of Fine Chemicals, Dalian University of Technology. Her research is focused on fluorescent dye-based probes and their biological applications.\nmannose-nanomicelles (BTM-NMs) were incubated in medium for 72 h, revealing their excellent stability. BTM-NMs were selectively taken up by MDA-MB-231 breast cancer cells (mannose receptor positive) via mannose-mediated endocytosis and localized in lysosomes. BTM-NMs induced 1O2 generation under irradiation (665 nm, 20 mW cm−2), resulting in lysosomal disruption, allowing the NPs to escape from the lysosomes to the cytoplasm and enabling 1O2 to further reach cellular components to achieve enhanced PDT (Figure 2c). This work nicely demonstrated the potential of BODIPY nano-photosensitizers for application in tumor-targeted anticancer phototherapy.\nZhou et al. designed supramolecular triangles with vertices comprising novel Pt(II) complexes and edges comprising\nSmall 2019, 1804927\n1804927 (3 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\npyridyl-functionalized BODIPY.[62] In this design, the BODIPY cores within the triangles were used as PDT PSs, while the presence of Pt(II) complexes were for chemotherapy (Figure 3a). 1 and 2 displayed strong fluorescence after being excited at 365 nm with an emission peak at ≈577 nm, which was originated from the BODIPY cores. The high fluorescence quantum yield in water (1, 6.9%; 2, 13.5%) was due to the ideal distance between Pt(II) and BODIPY, preventing Pt-induced fluorescence quenching via the heavy atoms. For biological applications, NPs containing compound 1 or 2 were prepared through self-assembly. The average hydrodynamic diameters of the two types of NPs were both between 40 and 50 nm. Once endocytosed by cells, the NPs localized in H+-enriched lysosomes or endosomes, where BODIPY and Pt(II) were released for PDT and chemotherapy. NPs containing compound 2 demonstrated better anticancer efficacy than those containing compound 1 in in vitro experiments, possibly arising from the higher cytotoxicity caused by Pt(II) and higher internalization efficiency (Figure 3b,c). These studies indicated that nanophotosensitizers 1 and 2 were potentially suitable for application in imaging-guided synergistic cancer therapy for PDT and chemotherapy."
    }, {
      "heading" : "2.2. BODIPY Nano-Photosensitizers from Supramolecular Interactions",
      "text" : "In addition to being driven by direct small molecule selfassembly, assembly can also be driven by supramolecular host–guest interactions, which can form nanomaterials via noncovalent interactions.[63] For instance, Zagami et al. reported nanoassemblies induced by host–guest interactions between nonionic amphiphilic α-cyclodextrin (α-CD) and halo-alkyl- tailored iodinated BODIPY (Figure 4).[64] The formed nanosystems were fairly stable, as the absorption and mean hydrodynamic diameter of the nanoparticle dispersion remained constant in water, phosphate-buffered saline (PBS), and physiological saline (NaCl, 0.9 wt%) even after a 2 week incubation. The 1O2 quantum yield of the nano-photosensitizer measured in water was 0.48. In vivo experiments were not conducted; however, the nanosystem was easily detected in the cytoplasm of cancer cells and showed toxicity upon irradiation, demonstrating the potential of the nanosystem for applications in cancer PDT. Zhang et al. applied heptamannosylated β-CD to mediate the formation of an adamantane (Ad)-functionalized BODIPY\nSmall 2019, 1804927\n1804927 (4 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nNPs (BODIPY with adamantine (BTA)@CD-Man7) via strong β-CD/Ad interactions (Figure 5a).[65] BTA@CD-Man7 NPs (117.2 ± 16.0 nm) were selectively internalized by cancer cells and localized in lysosomes (Figure 5b). After treatment with BODIPY NPs without targeting groups for 30 min under light irradiation (665 nm, 20 mW cm−2), the cell viability was 89%. In contrast, less than 9% of the cells were viable after incubation with mannose-modified NPs under identical conditions, demonstrating that mannose receptor–mediated endocytosis improved nanoparticle internalization. Furthermore, no significant cytotoxicity was observed for the NPs in the dark, and tumor growth was considerably inhibited when mice were treated with BTA@CD-Man7 under irradiation (665 nm, 20 mW cm−2, 30 min) (Figure 5c). The host–guest interaction approach employed here both induced nanoparticle formation and provided an easier alternative for incorporating tumor-targeting groups in nanosystems.\nNoncovalent interactions can also endow nanomaterials with tumor-specific sensitivity and controllable photoactivity.[63] Meng et al. developed supramolecular vesicles by using a BODIPY-functionalized quaternary ammonium derivative (guest) with a water-soluble pillar[5] arene (WP5, host) (Figure 6a,b).[66] The binding affinity for such a supramolecular system (WP5⊃G) was mainly driven by the cooperative electrostatic and hydrophobic interactions. The WP5 host is water soluble in the form of a carboxylic sodium salt, but it precipitates from water when the salt is transformed to carboxylic acid. The dissolution– precipitation of WP5 could be reversibly adjusted\nby modifying the solution pH, which allows the above-proposed supramolecular vesicles to achieve pH responsiveness. Moreover, anticancer drug doxorubicin (DOX) could be encapsulated in the nanostructures. DOX-loaded vesicles were internalized by cancer cells via endocytosis and localized in the lysosomes, where the low pH of the microenvironment triggered vesicle disassembly to release DOX and BODIPY. Thus, the vesicles were employed for both pH-modulated chemotherapy and PDT. Due to the good biocompatibility of the vesicles, normal cells retained a viability above 85% even after incubation at the maximum measured dose of 20 × 10−6 m. However, the photocytotoxicity (690 nm, 1.5 J cm−2) of the DOX-loaded vesicles to cancer cells was significant (half maximal inhibitory concentration (IC50) = 1.40 × 10−6 m, Figure 6c). Furthermore, the DOXloaded vesicles achieved synergistic chemo- and photodynamic activities, making these systems suitable for dual chemo-photodynamic therapy. However, the vesicles were not applied in vivo, as the mean diameter of the vesicles (245 nm, with a wall thickness of 6 nm) was unsuitable for EPR effect (Figure 6b). Further tuning of the vesicle size is essential for future biological applications."
    }, {
      "heading" : "2.3. BODIPY Nano-Photosensitizers Prepared from Polymer Encapsulation",
      "text" : "BODIPY nano-photosensitizers prepared via direct small molecule self-assembly and supramolecular host–guest interactions\nSmall 2019, 1804927\n1804927 (5 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\ndemonstrate enhanced water solubility and tumor accumulation compared with free BODIPY PSs. However, stabilizing these NPs is difficult due to their high critical micelle concentration (CMC), which can cause the undesired leakage of PSs in the blood stream during circulation. The aforementioned problem hinders the clinical transition of BODIPY nano- photosensitizers. Polymeric NPs, owing to their low CMC value, and adaptable compositions, sizes, and surface properties, are potentially suitable drug carriers in therapeutic fields. Naturally, extracted or synthetic polymers, such as polypeptides, polycaprolactone (PCL), polylactic acid (PLA), and PEG, have been widely used in constructing nanocarriers.[67] In most cases, the core–shell structure of polymeric nanoparticles comprises a hydrophilic surface layer for stabilizing in blood circulation and a hydrophobic interior core for loading therapeutic agents including anticancer drugs or PSs.[68,69] Encapsulating BODIPY PSs with a tumor-targeting amphiphilic polymer to generate nano-photosensitizers is a promising strategy to overcome the drawbacks of self-assembly NPs and enhance photosensitizer concentration in the tumor.[58,70–75] Shi et al. grafted diiodostyryl BODIPY to hyaluronic acid (HA), causing the spontaneous assembly of uniform NPs in water with a mean diameter of 50 nm (Figure 7).[73] These NPs exhibited specific tumor targeting due to the overexpression of the HA receptor, CD44, in tumor cells. After entering the lysosomes, the NPs were degraded by hyaluronidase, resulting in\nSmall 2019, 1804927\n1804927 (6 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nthe on-site activation of 1O2 in tumor cells (Figure 7b). In vivo experiments showed that the NPs effectively suppressed tumor growth, demonstrating their high potential for photodynamically activated cancer therapy in a clinical setting. This study solved the problem of the off-targeted activation of PSs, further reducing the PDT side effects.\nTo achieve PDT in deep tissue, an NIR light-activated BODIPY PS was synthesized and used to fabricate nano-photosensitizers.[70] After the conjugated system was expanded and Br atoms were introduced into the BODIPY core, an NIR BODIPYBr2 PS with high 1O2 quantum yield was developed for NIR activation (Figure 8).[76] Several nano-photosensitizers were constructed for PDT on the basis of NIR BODIPYBr2.\nLiu et al. reported a galactose-targeted amphiphilic polypeptide copolymer, poly(6-O-methacryloyl-d-galactopyranose)– poly(oligo(ethylene glycol)methacrylate–poly(N ε-carbobenzoxyl-lysine) (PMAGP–POEGMA–PLys), as a nanocarrier for NIR BODIPYBr2, which could be activated by NIR light (above 700 nm, Figure 9).[58] The PMAGP on the particle surface targeted hepatoma carcinoma cells; POEGMA functioned as a hydrophilic shell for nanoparticle stabilization; and PLys formed a hydrophobic core for loading the BODIPY. In a cell viability tests performed on HepG2 cells, the galactosetargeting NP demonstrated superior cell suppression compared to the NP without targeting ligands in the presence of light. However, this difference was not observed in HeLa cells (negative control group). In addition, poly(6-O-methacryloyld-galactopyranose)–poly(oligo(ethylene glycol)methacrylate)–\npoly(N ε-carbobenzoxy-l-lysine)–NIR BODIPYBr2 (PMAGP– POEGMA–PLys–B) was used for fluorescence imagingguided PDT. Notably, the activation wavelength of the nanophotosensitizer is within the NIR region, which is preferable to visible light for deep tissue penetration.\nPolymeric NPs can sense and respond to environmental changes via different chemical and physical mechanisms that often originate from dynamic hierarchical architectures.[77] Internal triggers, including pH, redox potential, temperature, and ionic strength permit temporally and spatially controlled drug delivery.[67,78] For instance, pH responsiveness is one of the most extensively exploited triggers, as pH values vary between different tissues and cellular compartments. The environment of cancer tissues is more acidic (pH 6.5–6.8) than blood and normal tissues (pH 7.0–7.4), while the pH value in cellular endo/lysosomes is even lower (pH 4.5–5.0).[79–81] The lower pH value of cancer cell endo/lysosomes promotes matrix degradation, and specifically leads to the release of PSs from nanocarriers for enhanced PDT. Liu et al. synthesized pHsensitive polypeptides (POEGMA–PAsp) via the ring-opening polymerization of an N-carboxyanhydride monomer to encapsulate the same NIR BODIPYBr2 PS (Figure 10a).[75] The POEGMA section was hydrophilic, while the inner part of PAsp was hydrophobic for loading BODIPYBr2. The core–shell structured micelles were degraded to release BODIPYBr2 at low pH conditions. For example, at pH 5.5, the photosensitizer release was rapid and sustained for up to 96 h, achieving 60% release in total (Figure 10b). Cell experiments showed that\nSmall 2019, 1804927\n1804927 (7 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nunder extremely low power density (20 mW cm−2), the HepG2 cell death rate was ≈45% higher than that of the control cells in the dark (Figure 10c).\nAlthough the NIR BODIPY PS was used in the above two examples, in vivo applications were not achieved, which may be due to the hypoxic microenvironment of the tumor.[58,75,82] Furthermore, O2 consumption during PDT further aggravates the hypoxia of tumors, which in turn prevents PDT from achieving its full effect.[83] Yuan et al. developed one strategy for overcoming the problem of tumor hypoxia by using self-sufficient O2-fluorinated polypeptide NPs as the carriers and the same NIR BODIPYBr2 PS (Figure 11a,b).[74] The unique electronic nature of CF bonds endowed the perfluorocarbons with excellent O2 affinity. POEGMA was selected as a hydrophilic segment and poly(b-benzyl-l-aspartate) (PBLA) was selected as a modifiable hydrophobic block. The two sections were conjugated to form a nonfluorinated control polymer POEGMA-b-PBLA (PB) via a click reaction. Fluoride 1H, 1H-heptafluorobutylamine (HFB) was then added to the side chain as the O2 carrier, as the unique electronic nature of the CF bonds endow the perfluorocarbons with excellent O2 affinity. In aqueous solution, PHFB self-assembled into micelles that were efficiently taken\nup by cancer cells. Due to the enhanced O2 capacity and 1O2 lifetime of the perfluorocarbons, the final nano-PDT agent demonstrated enhanced 1O2 production, resulting in high PDT efficiency. The light irradiation of the nano-photosensitizers considerably increased their cytotoxicity to cancer cells compared with that of the nonfluorinated polymer in a hypoxic environment (Figure 11c). The in vivo PDT efficacy of the PHFB/BODIPY NPs was further investigated on 4T1 tumorbearing mice (tumors on both sides). Compared with that of the PBS group, the growth of tumors treated with PB/BODIPY + light (635 nm, 100 mW cm−2, 10 min) was inhibited, while PDT using PHFB/BDP NPs at the same irradiation dose demonstrated the most significant tumor growth inhibition. The excellent PDT efficiency of PHFB/BDP was ascribed to its O2 carrying capacity, and was improved the PDT efficiency compared with the particles without oxygen supply.\nUsing perfluorocarbon nanomaterials as the O2 supplier partially solved the issue of inefficient PDT resulting from tumor hypoxia. However, this approach showed limited O2-carrying capacity.[84] Additionally, the instability of the perfluorocarbon nanomaterials also led to O2 leakage. These limitations hindered further medical applications. To overcome this problem,\nSmall 2019, 1804927\n1804927 (8 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nfunctional materials were used to induce O2 production inside the tumor, providing an effective approach. For instance, manganese dioxide (MnO2) is able to produce O2 via reaction with H2O2, which is expected to supply O2 to the tumor microenvironment as the concentration of H2O2 is higher therein.[85] Moreover, due to their pH sensitivity, MnO2 nanosheets are rapidly decomposed at low pH conditions.[86] Therefore, these can be used as pH-responsive drug carriers, resulting in the release of therapeutic agents in acidic tumor microenvironments. In this respect, Liu et al. prepared MnO2 containing multifunctional polypeptide NPs encapsulating NIR BODIPYBr2 through a simple one-step amino-based reduction reaction, followed by an emulsion encapsulating strategy. An amphiphilic block polymer was designed and synthesized, in which POEGMA functioned as the hydrophilic shell, and peptides as the hydrophobic core (Figure 12a).[83] These NPs could load MnO2 and efficiently deliver NIR BODIPYBr2. Because MnO2 reacts strongly with H2O2 to produce O2, the nanosystem reversed tumor hypoxia and improved the 1O2 production yield. The mortality of HepG2 and 4T1 cells treated with H2O2 and light irradiation (25 mW cm−2) under hypoxic conditions increased dramatically compared to that of cells in dark conditions (Figure 12b,c). An important challenge associated with PDT is the low ROS production of traditional PSs; thus, efforts have been made to improve the efficiency of ROS generation. The first example was reported by Huang et al., who introduced a carbazole moiety to BODIPY (Car–BDP, Figure 13a).[70] Car–BDP showed a more intense and broad red-to-NIR absorption band (600−800 nm) than traditional that of BODIPY PSs. In addition, Car–BDP demonstrated a much higher 1O2 quantum yield (ΦΔ = 67%) due to a large molar extinction coefficient (9.9 × 104 m−1 cm−1) and a low fluorescence quantum yield (ΦF = 4%). After encapsulation with tumor-targeting biodegradable poly(lactic acid)– poly(ethylene glycol)–folic acid (PLA–PEG–FA) polymers, Car–BDP formed stable NPs with an average diameter of 23.8 nm. Importantly, the NPs could be activated with a costeffective ultralow power lamp (12 mW cm−2, 670−800 nm) rather than the typically used laser light and demonstrated exceptional anticancer treatment in different cancer cell lines. In an in vivo experiment, mice bearing subcutaneous 4T1 tumor xenografts were selected as an animal model. The fluorescence at the tumor site gradually increased and reached a maximum of 24 h after the nanoparticles were injected, indicating that folate on the nanoparticle surface improved tumor targeting. The tumor growth inhibition was ≈90% after the Car–BDP– TNM treatment with lamp light irradiation (670−800 nm,\nSmall 2019, 1804927\n1804927 (9 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\n12 mW cm−2). Moreover, to determine whether the nano-photosensitizers could eliminate tumors in deep tissue, tumors covered with an 8 mm pock tissue were irradiated after intravenous injections of Car–BDP–TNM (Figure 13b–e). The tumor growth inhibition efficiency was well maintained (≈80%). In addition, serious necrosis was observed in the hematoxylin and eosin (H&E) staining after the PDT treatment (Figure 13e). These results indicated that the NPs could be activated for highly efficient deep tissue PDT. It is worth emphasizing that this was the first time deep-tissue tumor treatment, which was completed using low-power, incoherent NIR lamp irradiation.\nIn another example, Huang et al. reported a resonance energy transfer (RET) mechanism for constructing a novel dyad PS to enhance 1O2 generation (Figure 14a).[71] An energy-donor moiety (distyryl-BODIPY, B1) was attached to a PS (diiododistyryl-BODIPY, B2) to create the dyad molecule (RET–BDP). Unlike traditional PSs, the RET–BDP demonstrated unique advantages, such as increased absorption intensity, and significantly improved efficiency in concomitant 1O2 generation (1.9-fold 1O2 generation enhancement compared with that of\ndiiodo-distyryl-BODIPY, Figure 14b). This smart design considerably reduced the PS dosage and reduced the required power for the excitation light. After encapsulation with biodegradable copolymer Pluronic F-127-folic acid (F-127-FA), the resulting folic acid conjugated nanomicelles (RET–BDP–TNM) demonstrated excellent chemical and physical stability under physiological conditions with specific tumor targeting, leading to efficient in vivo tumor inhibition (Figure 14c). This study presented another new strategy for designing NIR-absorbing photosensitizers to enhance 1O2 generation efficiency.\nThe always-on property of PSs results in high background fluorescence and may reduce the treatment specificity.[86] This problem can be efficiently overcome by designing a PS that is activated in the tumor microenvironment,[87] which can be achieved using the concept of molecular logic gates.[88] In this case, only inputs to the tumor microenvironment such as low pH, thiols, or cancer-related enzymes together with light irradiation can lead to the output of toxic ROS. Tian et al. introduced diethylaminophenyl into an aza-BODIPYBr2 structure, which resulted in the photoinduced transfer (PET) process (Figure 15a).[72] As a consequence, the BODIPY PS demonstrated negligible fluorescence and 1O2 generation. After being dissolved in acidic conditions, H protons delay the PET process, restoring the NIR fluorescence and 1O2 generation. The pH-sensitive BODIPY was encapsulated into cyclic Arg–Gly– Asp (cRGD)-functionalized PEG–PLA nanomicelles (cRGDNEt2Br2BDP) to allow selective tumor imaging, and efficient PDT. The aza-BODIPY (NAB) NPs, which exhibited low toxicity in the dark, were strongly phototoxic to tumor cells via the generation of 1O2 activated by physiologically acidic pH and light irradiation. Another fascinating advantage of the system was its NIR implementation above 800 nm, which significantly improved the imaging sensitivity and increased the penetration depth. The therapeutic efficacy was reflected in situ and in real time, providing a valuable and convenient self-feedback function for PDT efficacy tracking.\nThe photoacoustic imaging (PAI) technology, which combines the advantages of optical and ultrasound imaging, is a promising imaging modality with a high spatial resolution and deep imaging depth (5−6 cm).[89–91] Therefore, it is ideally integrated into PDT systems to determine the degree of PS taken up by deep tissue, and evaluate the final therapeutic outcome. Hu et al. engineered lysosomes targeting BODIPY NPs by encapsulating an NIR-absorbed BODIPY derivative within amphiphilic 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)–mPEG5000 (BODIPY NPs, Figure 16a,b).[92] To produce an NIR-responsive BODIPY photosensitizer, a strongly electron-donating dimethylaminophenyl moiety was used to decorate the electron-withdrawing BODIPY core to form donor–π–acceptor (D–π–A) bis-styryl BODIPY, which displayed strong absorption at 760 nm with a molar absorption coefficient of 1.81 × 104 m−1 cm−1 (Figure 16c). Importantly, the attached dimethylaminophenyl is a representative acid-sensitive group exhibiting the PET effect, which enabled acid-activated PDT in acidic lysosomes. The viability of the cancer cells incubated with BODIPY NPs was dramatically decreased to 47.3% under laser irradiation at 730 nm with a power density of 200 mW cm−2. In an in vivo experiment, A549 tumor growth was significantly inhibited through PAI-guided PDT treatment.\nSmall 2019, 1804927\n1804927 (10 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com"
    }, {
      "heading" : "3. BODIPY Nano-Photosensitizers for PTT",
      "text" : "PTT also requires PSs with high NIR absorption for deep-tissue penetration, a large absorption coefficient for superior photoactivity with sufficient heat, and good photostability to allow efficient treatment without photobleaching.[34] Through chemical modification with a conjugated system, BODIPY-based nanophotosensitizers have a high absorption coefficient in the NIR region, which is favorable for deep-tissue applications. The excellent photostability of these nano-photosensitizers endows them with durable phototoxicity toward tumors. Moreover, reducing the fluorescence and 1O2 quantum yield by employing the PET process could further improve the nonradiative relaxation probability, enhancing the efficiency of photothermal conversion for PTT.[35] Therefore, BODIPY PSs have also been used for PTT. For instance, Xu et al. constructed an NIR aza-BODIPY (A1) functioning as two dimethylamine moieties. In this design, the dimethylamine groups were the electron donors, and the aza-BODIPY core was the electron acceptor (Figure 17).[35] Compared with the control compound without dimethylamine moieties (A2), the newly designed BODIPY demonstrated a short photoluminescence lifetime (1.4 vs 4.5 ns), a low radiative quantum yield (0.003 vs 0.068), and a large nonradiative transition rate (Knr = 7.2 × 108 s−1 vs Knr = 2.4 × 108 s−1) caused by PET (Figure 17b–e). More importantly, under identical irradiation conditions, the PS showed a higher temperature change, indicating an enhanced photothermal effect. After encapsulation with the biodegradable polymer DSPE−mPEG5000, the formed nano-photothermal agents (≈43.0 nm) exhibited excellent water solubility and photostability. Following a low-dose injection of 0.05 mg kg−1 in vivo, the NPs accumulated efficiently in the tumor site via the EPR. The tumor site temperature increased rapidly to 53 ± 1 °C under 808 nm (500 mW cm−2) laser irradiation within 5 min, and achieved effective tumor ablation. This work provided a new concept of engineering PSs as photothermal agents via intramolecular PET. Organic dyes with excellent photostability can self-assemble with proteins such as bovine serum albumin (BSA) to form protein–dye nanostructures, which can be employed as photothermal therapeutic agents. Lu et al. designed core–shell Mn– 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (DBA)@BSA–PF NPs for magnetic resonance imaging (MRI) and light emitting diode (LED) light-driven water oxidation, with O2 generation attenuating hypoxia in cancer cells to achieve efficient phototherapy (Figure 18a).[93] Mn(II) is a potent T1-relaxation agent that can react with H2O2 or ROS to form a high\nSmall 2019, 1804927\n1804927 (11 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nportion of Mn(III/IV) species, resulting in MRI signal changes. Moreover, the photoresponsive Mn(II) complex/water system acted as a dioxygen and proton generator under hypoxic conditions. BSA was used to encapsulate Mn–DBA and stabilize the nanoparticle dispersion. To improve the tumor-targeting effect and biocompatibility of the NPs, the nanostructure surface was further grafted with PEG–polyethylene glycol-folic acid (FA) to form cancer targetable NPs (Mn–DBA@BSA–PF, 5 nm). Obvious oxygen bubbles were clearly observed when the Mn–DBA@BSA–PF NPs were added to an acidic environment under red LED light (630–700 nm) irradiation (Figure 18b). In comparison, when the reaction was performed in the dark, nearly no oxygen was generated. The photothermal conversion efficiency was calculated to be 17.9% when the suspensions were irradiated with continuous red LED light (630–700 nm, 4 W) for 10 min (Figure 18c). Oxygen generation could reverse the hypoxia in the tumor, improving the phototherapy effect. After intravenous injection of the Mn–DBA@BSA–PF NPs into tumor-bearing mice, an enhancement in the T1-weighted contrast was detected in the tumor area, suggesting that the NPs efficiently accumulated in the tumor tissues due to the EPR effect."
    }, {
      "heading" : "4. BODIPY Nano-Photosensitizers for Combined PDT and PTT",
      "text" : "Compared with PDT, PTT has emerged as a potentially safe option because the off-target sensitizing effects and irreversible oxidative damage by ROS are frequently observed during PDT.[94] Furthermore, most PDT agents are oxygen dependent\nSmall 2019, 1804927\n1804927 (12 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nand are ineffective in tumors with hypoxic environments.[31] On the other hand, photothermal agents normally require a high light density to generate heat, which may damage normal tissues during therapy.[31] Nevertheless, employing PTT alone may be inefficient for complete tumor ablation, and the remaining tumor cells can rapidly develop heat resistance, leading to the failure of PTT to cure cancer.[96,107] In contrast, the combination of PDT with PTT is promising for cancer treatment. Photothermal agents produce heat to conquer the tumor under hypoxic conditions and subsequently improve the PDT effect, while PDT agents can generate ROS to kill heat-resistant tumor cells to improve the photothermal therapeutic effect.[36] Thus, nano-photosensitizers that perform well in combined PDT and PTT are highly desirable.\nTang et al. conducted pioneering work by encapsulating NAB into polymer micelles (DSPE–mPEG2000) (Figure 19). The dimethylaminophenyl unit on BODIPY ensured the pH-sensitive property of the NAB NPs (Figure 19a).[95] The PET effect originating from the dimethylaminophenyl unit quenched 1O2 generation and the photothermal effect. After the PET process was quenched with H+ in the acidic tumor environment, the phototoxicity and fluorescence of the NAB NPs were restored (Figure 19b,c). Thus, the activity of the NAB NPs was much greater at pH 5.0 than at pH 7.4 during the 1O2 production under xenon lamp irradiation. In addition, the temperature of the NAB NP solution at pH 5.0 increased to ≈23.2 °C after 20 min of irradiation, which was 1.6 °C higher than that at pH 7.4. The NAB NPs demonstrated significant dose-dependent phototoxicity, while the cell viability remained over 70% without irradiation. After the intravenous injection of NAB NPs into HeLa tumor-bearing nude mice, the photoacoustic (PA) signal significantly increased and reached a maximum after 1 h. Phototherapy significantly inhibited tumor growth (90.7%) compared to the control group; these results showed that PDT combined with PTT was superior to the previously reported methods based on a single phototherapy mode (PDT or PTT).\nSmall 2019, 1804927\n1804927 (13 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nTo further enhance the phototherapy efficiency, efforts have been made to decrease the radiative transitions, thus ensuring the efficient singlet-to-triplet intersystem crossing or nonradiative transitions, which can be achieved through two strategies. First, fabricating BODIPY with halogenate substitutions is a commonly used method to decrease the radiative transitions (halogenated BODIPY). Second, some BODIPY molecules showing decreased radiative transitions are modified with heavy metal atoms (Pt(II)) or conjugated systems (nonhalogenated BODIPY)."
    }, {
      "heading" : "4.1. Halogenated BODIPY-Containing Nano-Photosensitizers",
      "text" : "Zhao et al. synthesized a series of aza-BODIPYs (B1–B4) and studied their PDT and PTT effects (Figure 20). In their design, aza-BODIPY with chlorine-, bromide-, or iodine substitutions was prepared.[96] To optimize the synergistic PDT and PTT effects, iodine-substituted aza-BODIPYs were further employed to prepare hydrophilic NPs (IABN, 142 nm) via encapsulation with DSPE–mPEG5000. IABN demonstrated significant 1O2\ngeneration due to the heavy atom effect of iodine. In addition, the photothermal conversion efficiency was calculated to be 34.8% under 730 nm laser irradiation (500 mW cm−2). The cancer cell viability was below 30% when the concentration of IABN was above 60 × 10−6 m after treatment with 730 nm laser irradiation (500 mW cm−2) for 5 min. In in vivo experiments, IABN showed substantial ROS generation and photothermal effects under the same irradiation conditions. Moreover, the NPs effectively inhibited tumor growth without producing significant side effects due to the synergistic therapeutic effects.\nAnother BODIPY PS was synthesized by Tang et al. for combined PDT and PTT (Figure 21).[97] Both iodine- and bromine substituents were introduced to the BODIPY skeleton to increase the 1O2 generation quantum yield. Water-soluble cubic IABDP NPs (150 nm) were prepared through a simple self-assembly strategy with the assistance of amphiphilic DSPE–mPEG2000. Compared with that of A BF2 chelate of [4-iodo-5-(4-bromophenyl)3-(4-methoxyphenyl)-1H-pyrrol-2-yl][4-iodo-5-(4-bromophenyl)3-(4-methoxyphenyl)pyrrol-2-ylidene]amine (IABDP) (≈658 nm), the absorption of cubic IABDP was significantly redshifted, with two clear peaks at ≈721 and 772 nm, which were assigned\nSmall 2019, 1804927\n1804927 (14 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nto the structure specific intermolecular interaction and charge transfer, respectively. Under broadband irradiation with a xenon lamp, IABDP in a physiological solution (PBS at pH 7.4) efficiently produced 1O2 and increased the temperature by 28.3 °C after 20 min of irradiation. The viability of cancer cells (HeLa) incubated with different concentrations of IABDP under xenon lamp irradiation decreased significantly in a dosedependent manner with an IC50 of ≈47 × 10−6 m. In contrast, the untreated cells in the dark showed slight toxicity with a cell viability of ≈80% in a high-concentration range (⪆40 × 10−6 m). In vivo experiments showed that the IABDP NPs significantly inhibited tumor growth (87.2% inhibition compared to that of\nSmall 2019, 1804927\n1804927 (15 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nthe control group) and were superior to the previously reported methods based on a single phototherapy mode (PDT or PTT), testifying the advantage of synergistic therapy. In addition, no obvious histological alterations were observed in the group injected with IABDP, further confirming the in vivo biocompatibility of the NPs.\nA typical hydrophobic fluorescent dye, BODIPY, could easily aggregate in aqueous solution, leading to inefficient PDT.[57] However, BODIPY aggregation can be systematically regulated in conformations involving both side-by-side (J-type) and face-toface (H-type) interactions, producing aggregates with low fluorescence, but high ROS quantum yield and photothermal conversion efficiency. Based on the above concept, He et al. developed wavelength-dependent photoconversion regulation of BODIPY with iodine modification through polymeric vesicles (PEG45–PCL60– poly(N-isopropyl-acrylamide) (PNIPAM)33) for either PDT or PTT (Figure 22).[98] The vesicles exhibited a 98.0% entrapment efficiency at a 20% drug-loading level, due to the hydrophobicity of BODIPY. The presence of both J-type and H-type BODIPY aggregates in the spatially limited vesicular membrane allowed the vesicles to be excited by NIR light (785 nm) to perform distinct PTT through nonradiative transitions without much 1O2 generation. Meanwhile, under red light irradiation (660 nm), the vesicles displayed remarkable 1O2 generation mainly via the singlet-to-triplet transition for PDT. Specifically, the vesicles\nexhibited a 1O2 quantum yield of 0.43 under 660 nm irradiation at 0.5 W cm−2; in contrast, this value was 0.057 under 785 nm irradiation at the same power intensity. The photothermal conversion efficiencies were 16% and 29% under 660 and 785 nm irradiation, respectively, at 500 mW cm−2. In vivo experiments were conducted in which the initial tumor volume exceeded 60 mm3. The hypoxic microenvironment of the solid tumor diminished the PDT effect. Therefore, PTT contributed most of the phototoxicity during treatment. Thus, the vesicles achieved complete tumor ablation without any regrowth under 785 nm irradiation. However, it was impossible to eradicate the tumor cells by using 660 nm irradiation due to the lower PTT efficiency. This study provides a completely new strategy to tuning the photoconversion of organic fluorophores to achieve potent phototherapies.\nSynergistic phototherapies can be further combined with chemotherapy. Although chemotherapy is widely used in clinics for cancer treatment, its therapeutic effects have been severely hindered by the inherent limitations of chemotherapeutic drugs (e.g., high systemic toxicity and low targeting ability).[36,99–101] Furthermore, in most cases, tumor resistance to chemotherapeutic drugs occurs almost universally during chemotherapy, together with serious neoplasm metastasis and proliferation.[102–106] Synergistic therapy involving PDT, PTT, and chemotherapy is of great interest for combating drug resistance and improving therapeutic efficacy. Recently, Chen et al. developed\nSmall 2019, 1804927\n1804927 (16 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nan iodine-modified aza-BODIPY PS with a high 1O2 quantum yield (0.82 in dichloromethane). PEG–DOX-encapsulated azaBODIPY nanoparticles (DAB NPs) were then prepared in which DOX reacted with aldehyde-containing PEG to form a Schiff base (PEG–DOX), thereby leading to the release of DOX in an acidic environment (Figure 23).[107] The photothermal effect of DAB NPs was demonstrated by their relatively good photothermal conversion efficiency (38.3%) under 660 nm laser irradiation. The calculated DOX and aza-BODIPY loading rates for the DAB NPs were 12.8% and 6.0%, respectively. The DAB NPs demonstrated excellent photo-cytotoxicity under xenon lamp irradiation, which considerably exceeded that of nonirradiated DAB NPs. Additionally, the DAB NPs efficiently accumulated in the tumor site, as the fluorescence signal increased gradually in the tumor after only 1 h postinjection. Importantly, the tumor was eliminated after 12 days of treatment without tumor recurrence. In most examples of synergistic therapy using PDT and PTT, the tumors could only be controlled the tumors; this study represents one of the few cases in which the tumor could be completely eliminated by combined phototherapy and chemotherapy."
    }, {
      "heading" : "4.2. Nonhalogenated BODIPY Nano-Photosensitizers with High Phototherapy Efficiency",
      "text" : "A number of BODIPY nano-photosensitizers for combined PDT and PTT are modified with halogen atoms to decrease radiative transitions. However, these agents still display a highly fluorescence quantum yield, which is unconducive to highefficient phototherapy. To further decrease the radiative transition probability, Guo et al. designed self-assembled NPs with a platinized BODIPY core (Bodiplatin-NPs, Figure 24).[108] Pt possesses a high spin–orbit coupling constant (χ = 4481 cm−1) and can promote rapid intersystem crossing at a high rate of 1012 s−1. Additionally, Pt contains the unoccupied dx2−y2 orbitals of square planar Pt(II), which may promote nonradiative decay from the excited state to the ground state through the d–d energy band transition. After the BODIPY core was modified with Pt, the formed compound (Bodiplatin) demonstrated a high 1O2 quantum yield and a preferable photothermal conversion efficiency (0.28% and 27.0%, respectively) compared to those of BODIPY (0.02% and 11.0%, respectively) under red light irradiation (660 nm, 500 mW cm−2). PEGylated Bodiplatin was synthesized for in vivo applications by the conjugation of Bodiplatin–propyne with polyoxyethylene azide (MW = 5000); this product was further self-assembled into micellar Bodiplatin-NPs. Compared with Bodiplatin, Bodiplatin-NPs exhibited higher 1O2 and photothermal conversion efficiencies (0.34% and 37%, respectively) due to their improved nonradiative decay within self-assembled nanostructures. Their triplet excited state lifetime was 2.51 µs, while that of BODIPY was not detectable. The NPs showed no significant cytotoxicity without irradiation even at a dose of 100 × 10−6 m\nSmall 2019, 1804927\n1804927 (17 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nbut caused severe cell damage (3.0 × 10−6 m IC50) under the clinically applied irradiation (660 nm, 150 mW cm−2) of breast cancer cells (4T1). More importantly, the Bodiplatin-NPs achieved a total tumor ablation with no regrowth. In contrast, the tumor regrew in the presence of ROS-scavenger vitamin C. The results demonstrated that the ROS-mediated PDT treatment played a key role in achieving synergistic therapy with tumor ablation.\nIn another example, Ye et al. induced the photoconversion of BODIPY from fluorescence to singlet-totriplet or nonradiative transitions by conjugated coupling (Figure 25).[109] For in vivo delivery, the hydrophobic conjugated dimeric BODIPY (di-BDP) and trimeric BODIPY (tri-BDP) were encapsulated in poly(ethylene glycol)114-bpoly(caprolactone)60 copolymer to form di-BDP-loaded NPs (di-BDP-NPs, 95.0 nm by dynamic light scattering (DLS)) and tri-BDP-loaded (tri-BDP-NPs, 82.0 nm by DLS) nanoparticles. The di-BDP-NPs and tri-BDP-NPs exhibited the redshifted absorption peaks at 649 and 738 nm in water, respectively, due to their conjugated conformations. The transient absorption spectra suggested that di-BDP and tri-BDP had triplet lifetimes (τ) of 93.6 and 70.6 µs, respectively, indicating that both NPs underwent efficient singlet-to-triplet transitions (the 1O2 quantum yields of di-BDP and tri-BDP\nSmall 2019, 1804927\n1804927 (18 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1804927\n1804927 (19 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nwere 0.25 and 0.18, respectively, and that for mono-BDP-NPs was 0.09). Furthermore, di-BDP-NPs and tri-BDP-NPs demonstrated the photothermal conversion efficiencies of 32.2% and 45.2%, respectively, under light (660 and 785 nm) exposure at 500 mW cm−2, while no significant photothermal conversion was observed for mono-BDP-NPs. Therefore, both conjugated BODIPY NPs were able to produce 1O2 and heat under irradiation. In vivo experiments showed that di-BDP-NPs and tri-BDP-NPs caused the temperature to increase by 10.2 and 18.0 °C under light irradiation (500 mW cm−2 for 5 min) at 660 or 785 nm, respectively. Thus, tri-BDP-NPs possessed a preferable ability to completely ablate tumors upon NIR light exposure compared with di-BDP-NPs, indicating that the phototherapy effect under 785 nm irradiation is preferable for achieving deeptissue penetration and appropriate 1O2 and heat generation. Moreover, this approach avoids the use of heavy atoms such as I and Br, provides a conventional strategy with potential safety concerns, and is a rational method for improving the phototherapy effect of BODIPY nano-photosensitizers."
    }, {
      "heading" : "5. Summary and Perspectives",
      "text" : "This review summarizes different types of BODIPY-based nano-photosensitizers and their applications for PDT, PTT, and combined PDT and PTT. These NP systems were prepared via dye precipitation, supramolecular interactions, and polymer encapsulation. BODIPY nano-photosensitizers are selectively taken up by tumor cells via the EPR effect and receptor-mediated cell endocytosis, which increase the therapeutic efficacy. Great achievements have been made in this research field. For instance, BODIPY nano-photosensitizers with NIR absorption and highly efficient 1O2 generation have been designed. Several examples with excitation wavelengths in the range 800–900 nm and 1O2 conversion in the range 30–60% were developed and applied for in vivo antitumor PDT. A few BODIPY nano-photosensitizers showing larger nonradiative transition rates were prepared for PTT, which can increase the tumor temperature efficiently and lead to cancer cell death. A number of BODIPYcontaining nano-photosensitizers prepared via the combination of PDT with PTT have been reported for cancer treatment. The\nSmall 2019, 1804927\n1804927 (20 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1804927\n1804927 (21 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\ncombined phototherapies can overcome the limitation of PDT caused by tumor hypoxia and that of PTT due to the required high-intensity irradiation. In addition, BODIPY nano-photosensitizers can combine with chemotherapy for synergistic treatment. One example reported by Chen and co-workers showing PDT, PTT, and chemotherapy demonstrated the most efficient anticancer performance of the three different treatment approaches.[107]\nDespite significant achievements in the area of anticancer phototherapy, much improvement needs to be made to further achieve clinical applications. One challenge is to improve the cellular uptake of these nano-photosensitizers. Compared to that of commercial anticancer drugs or PSs, the cellular uptake efficiency of current BODIPY-containing nano-photosensitizers is low, and thus needs further enhancement. Efforts can be focused on exploring active targeting strategies to improve the endocytosis. In addition, to ensure a long triplet lifetime, current BODIPY PSs are usually modified with heavy atoms including Br, I, and Pt. However, compared to commercial photosensitizers such as indocyanine green (ICG) and chlorine6 (Ce6), the presence of heavy atoms may cause toxicity. Therefore, exploiting heavy-atom-free BODIPY nano-photosensitizers\nwith a long triplet lifetime is a promising approach for achieving future clinical transitions.\nBODIPY-containing nano-photosensitizers that are responsive to cancer microenvironments have been shown to improve the PDT specificity and reduce toxic side effects. Most BODIPY nano-photosensitizers activated by tumor microenvironments respond to low pH. However, some tissues, such as inflammatory tissues, also feature low-pH environments, and BODIPY nano-photosensitizers may generate phototoxicity toward nontumor tissues. Thus, BODIPY nano-photosensitizers that are responsive to more specific tumor microenvironment markers such as enzymes are expected to be designed for highly specific cancer phototherapy.[110–112]\nPolymeric NPs are promising carriers for transporting BODIPY in the blood stream. However, PSs that are physically loaded in a hydrophobic core often leak out, which may result in long-term toxic side effects. Therefore, the design of new BODIPY polymeric NPs with reduced dye leakage is highly desirable. Two approaches may help to improve the loading stability. First, the rational design of a hydrophobic part within the polymer may form a strong interplay with the rigid structure of BODIPY through π–π interactions. Second, BODIPY PSs\nSmall 2019, 1804927\n1804927 (22 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1804927\n1804927 (23 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\ncould be attached to the polymer via stimuli-responsive covalent bonds that can be cleaved under corresponding stimuli to release free PSs into tumor tissues.\nTo improve the treatment efficiency, combining phototherapy with chemotherapy is a practical and effective strategy; chemotherapy could overcome the limited tissue penetration of phototherapy, and phototherapy could reduce the drug dosages to reduce the side effects caused by chemotherapy. However, a few BODIPY-based nano-photosensitizers are combined with chemotherapy for cancer treatment. This combination strategy should be vigorously developed in the future.\nAs a rapidly developing form of treatment, immunotherapy has been confirmed to be effective in treating metastatic neoplasms; however, its development is limited by its low therapeutic efficacy for solid tumors. Combining phototherapy with immunotherapy can both improve the inhibition of solid tumors and prevent cancer metastasis. However, until recently there were no reports on the use of BODIPY nanoagents for synergistic phototherapy and immunotherapy; thus, this combination treatment should be performed to advance cancer therapy.\nAlthough research on BODIPY nano-photosensitizers remains in its infancy and faces ongoing challenges, we are strongly convinced that phototherapy based on BODIPY nanoagents will play an essential role in anticancer treatment, due to its excellent photophysical and photochemical properties and important anticancer performance."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was financially supported by National Science Foundation of China (Grant Nos. 21576037, 21878039, 21676047, 21421005, and 21808028), NSFC-Liaoning United Fund (U1608222), and the Fundamental Research Funds for the Central Universities (2018011013). The authors thank Ivyspring International Publisher for the use of Figure 12.[83]"
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Keywords",
      "text" : "BODIPY, nano-photosensitizers, near-infrared light, photodynamic therapy, photothermal therapy\nReceived: November 22, 2018 Revised: January 11, 2019\nPublished online:\n[1] W. Fan, P. Huang, X. Chen, Chem. Soc. Rev. 2016, 45, 6488. [2] L. Cheng, C. Wang, L. Feng, K. Yang, Z. Liu, Chem. Rev. 2014, 114,\n10869. [3] P. Yang, S. Gai, J. Lin, Chem. Soc. Rev. 2012, 41, 3679. [4] L. Li, F. Tang, H. Liu, T. Liu, N. Hao, D. Chen, X. Teng, J. He, ACS\nNano 2010, 4, 6874.\n[5] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nat. Nanotechnol. 2007, 2, 751. [6] S. H. Voon, L. V. Kiew, H. B. Lee, S. H. Lim, M. I. Noordin, A. Kamkaew, K. Burgess, L. Y. Chung, Small 2014, 10, 4993. [7] X. Zhao, M. Li, W. Sun, J. Fan, J. Du, X. Peng, Chem. Commun. 2018, 54, 7038. [8] K. Han, S. Wang, Q. Lei, J. Zhu, X. Zhang, ACS Nano 2015, 9, 10268. [9] J. Gao, J. Li, W. Geng, F. Chen, X. Duan, Z. Zheng, D. Ding, D. Guo, J. Am. Chem. Soc. 2018, 140, 4945. [10] D. Ni, C. A. Ferreira, T. E. Barnhart, V. Quach, B. Yu, D. Jiang, W. Wei, H. Liu, J. W. Engle, P. Hu, W. Cai, J. Am. Chem. Soc. 2018, 140, 14971. [11] X. Zhuang, X. Ma, X. Xue, Q. Jiang, L. Song, L. Dai, C. Zhang, S. Jin, K. Yang, B. Ding, P. C. Wang, X. Liang, ACS Nano 2016, 10, 3486. [12] I. S. Turan, D. Yildiz, A. Turksoy, G. Gunaydin, E. U. Akkaya, Angew. Chem., Int. Ed. 2016, 55, 2875. [13] X. Li, N. Kwon, T. Guo, Z. Liu, J. Yoon, Angew. Chem., Int. Ed. 2018, 57, 11522. [14] C. Yang, Y. Chen, W. Guo, Y. Gao, C. Song, Q. Zhang, N. Zheng, X. Han, C. Guo, Adv. Funct. Mater. 2018, 28, 1706827. [15] X. Zheng, L. Wang, S. Liu, W. Zhang, F. Liu, Z. Xie, Adv. Funct. Mater. 2018, 28, 1706507. [16] S. Luo, X. Tan, S. Fang, Y. Wang, T. Liu, X. Wang, Y. Yuan, H. Sun, Q. Qi, C. Shi, Adv. Funct. Mater. 2016, 26, 2826. [17] H. Huang, S. Long, M. Li, F. Gao, J. Du, J. Fan, X. Peng, Dyes Pigm. 2018, 149, 633. [18] X. Li, S. Yu, D. Lee, G. Kim, B. Lee, Y. Cho, B. Zheng, M. Ke, J. Huang, K. T. Nam, X. Chen, J. Yoon, ACS Nano 2018, 12, 681. [19] W. Sun, Y. Wen, R. Thiramanas, M. Chen, J. Han, N. Gong, M. Wagner, S. Jiang, M. S. Meijer, S. Bonnet, H. Butt, V. Mailänder, X. Liang, S. Wu, Adv. Funct. Mater. 2018, 28, 1804227. [20] L. Liu, Y. Zhang, W. Qiu, L. Zhang, F. Gao, B. Li, L. Xu, J. Fan, Z. Li, X. Zhang, Small 2017, 13, 1701621. [21] M. Li, J. Xia, R. Tian, J. Wang, J. Fan, J. Du, S. Long, X. Song, J. W. Foley, X. Peng, J. Am. Chem. Soc. 2018, 140, 14851. [22] W. Wu, X. Shao, J. Zhao, M. Wu, Adv. Sci. 2017, 4, 1700113. [23] Y. Wang, G. Wei, X. Zhang, F. Xu, X. Xiong, S. Zhou, Adv. Mater.\n2017, 29, 1605357. [24] X. Li, S. Lee, J. Yoon, Chem. Soc. Rev. 2018, 47, 1174. [25] Z. Dong, L. Feng, Y. Hao, M. Chen, M. Gao, Y. Chao, H. Zhao,\nW. Zhu, J. Liu, C. Liang, Q. Zhang, Z. Liu, J. Am. Chem. Soc. 2018, 140, 2165. [26] B. Zhou, Y. Li, G. Niu, M. Lan, Q. Jia, Q. Liang, ACS Appl. Mater. Interfaces 2016, 8, 29899. [27] X. Meng, W. Li, Z. Sun, J. Zhang, L. Zhou, G. Deng, P. Gong, L. Cai, J. Mater. Chem. B 2017, 5, 9405. [28] J. Liu, H. Liang, M. Li, Z. Luo, J. Zhang, X. Guo, K. Cai, Biomaterials 2018, 157, 107. [29] J. Robinson, S. Tabakman, Y. Liang, H. Wang, H. Sanchez Casalongue, D. Vinh, H. Dai, J. Am. Chem. Soc. 2011, 133, 6825. [30] Y. Wang, G. Wei, X. Zhang, X. Huang, J. Zhao, X. Guo, S. Zhou, Small 2018, 14, 1702994. [31] H. S. Jung, J. Lee, K. Kim, S. Koo, P. Verwilst, J. L. Sessler, C. Kang, J. S. Kim, J. Am. Chem. Soc. 2017, 139, 9972. [32] X. Li, X. Peng, B. Zheng, J. Tang, Y. Zhao, B. Zheng, M. Ke, J. Huang, Chem. Sci. 2018, 9, 2098. [33] K. K. Ng, G. Zheng, Chem. Rev. 2015, 115, 11012. [34] H. S. Jung, P. Verwilst, A. Sharma, J. Shin, J. L. Sessler, J. S. Kim,\nChem. Soc. Rev. 2018, 47, 2280. [35] Y. Xu, T. Feng, T. Yang, H. Wei, H. Yang, G. Li, M. Zhao, S. Liu,\nW. Huang, Q. Zhao, ACS Appl. Mater. Interfaces 2018, 10, 16299.\nSmall 2019, 1804927\n1804927 (24 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\n[36] G. Pan, H. Jia, Y. Zhu, R. Wang, F. Wu, Z. Chen, ACS Biomater. Sci. Eng. 2017, 3, 3596. [37] X. Li, B. Zheng, X. Peng, S. Li, J. Ying, Y. Zhao, J. Huang, J. Yoon, Coord. Chem. Rev. 2019, 379, 147. [38] Q. Chen, L. Feng, J. Liu, W. Zhu, Z. Dong, Y. Wu, Z. Liu, Adv. Mater. 2016, 28, 7129. [39] K. Liu, R. Xing, Q. Zou, G. Ma, H. Möhwald, X. Yan, Angew. Chem., Int. Ed. 2016, 55, 3036. [40] M. Li, S. Long, Y. Kang, L. Guo, J. Wang, J. Fan, J. Du, X. Peng, J. Am. Chem. Soc. 2018, 140, 15820. [41] X. Li, D. Lee, J.-D. Huang, J. Yoon, Angew. Chem., Int. Ed. 2018, 57, 9885. [42] A. P. Thomas, L. Palanikumar, M. T. Jeena, K. Kim, J. Ryu, Chem. Sci. 2017, 8, 8351. [43] A. Turksoy, D. Yildiz, E. U. Akkaya, Coord. Chem. Rev. 2019, 379, 47. [44] M. Li, R. Tian, J. Fan, J. Du, S. Long, X. Peng, Dyes Pigm. 2017, 147, 99. [45] S. Kolemen, E. U. Akkaya, Coord. Chem. Rev. 2018, 354, 121. [46] G. Shen, R. Xing, N. Zhang, C. Chen, G. Ma, X. Yan, ACS Nano\n2016, 10, 5720. [47] Y. Li, L. Yan, K. Liu, J. Wang, A. Wang, S. Bai, X. Yan, Small 2016,\n12, 2575. [48] Y. Liu, D. Zhang, Z. Qiao, G. Qi, X. Liang, X. Chen, H. Wang, Adv.\nMater. 2015, 27, 5034. [49] L. He, Y. Huang, Y. Chang, Y. You, H. Hu, K. W. Leong, T. Chen,\nJ. Mater. Chem. B 2017, 5, 8228. [50] H. Chen, W. Zhang, G. Zhu, J. Xie, X. Chen, Nat. Rev. Mater. 2017,\n2, 17024. [51] W. Sun, S. Li, B. Häupler, J. Liu, S. Jin, W. Steffen, U. S. Schubert,\nH. Butt, X. Liang, S. Wu, Adv. Mater. 2017, 29, 1603702. [52] B. Li, L. Lu, M. Zhao, Z. Lei, F. Zhang, Angew. Chem., Int. Ed.\n2018, 57, 7483. [53] Y. Fan, P. Wang, Y. Lu, R. Wang, L. Zhou, X. Zheng, X. Li,\nJ. A. Piper, F. Zhang, Nat. Nanotechnol. 2018, 13, 941. [54] P. Wang, Y. Fan, L. Lu, L. Liu, L. Fan, M. Zhao, Y. Xie, C. Xu,\nF. Zhang, Nat. Commun. 2018, 9, 2898. [55] J. Zhao, D. Zhong, S. Zhou, J. Mater. Chem. B 2018, 6, 349. [56] L. Huang, G. Han, Small Methods 2018, 2, 1700370. [57] J. Zhao, K. Xu, W. Yang, Z. Wang, F. Zhong, Chem. Soc. Rev. 2015,\n44, 8904. [58] L. Liu, Z. Ruan, T. Li, P. Yuan, L. Yan, Biomater. Sci. 2016, 4, 1638. [59] C. Ji, Q. Gao, X. Dong, W. Yin, Z. Gu, Z. Gan, Y. Zhao, M. Yin,\nAngew. Chem., Int. Ed. 2018, 57, 11384. [60] Z. Ruan, Y. Zhao, P. Yuan, L. Liu, Y. Wang, L. Yan, J. Mater. Chem.\nB 2018, 6, 753. [61] Q. Zhang, Y. Cai, Q. Li, L. Hao, Z. Ma, X. Wang, J. Yin, Chem. - Eur.\nJ. 2017, 23, 14307. [62] J. Zhou, Y. Zhang, G. Yu, M. R. Crawley, C. R. P. Fulong,\nA. E. Friedman, S. Sengupta, J. Sun, Q. Li, F. Huang, T. R. Cook, J. Am. Chem. Soc. 2018, 140, 7730. [63] G. Yu, X. Zhao, J. Zhou, Z. Mao, X. Huang, Z. Wang, B. Hua, Y. Liu, F. Zhang, Z. He, O. Jacobson, C. Gao, W. Wang, C. Yu, X. Zhu, F. Huang, X. Chen, J. Am. Chem. Soc. 2018, 140, 8005. [64] R. Zagami, G. Sortino, E. Caruso, M. C. Malacarne, S. Banfi, S. Patanè, L. Monsù Scolaro, A. Mazzaglia, Langmuir 2018, 34, 8639. [65] Q. Zhang, Y. Cai, X.-J. Wang, J.-L. Xu, Z. Ye, S. Wang, P. H. Seeberger, J. Yin, ACS Appl. Mater. Interfaces 2016, 8, 33405. [66] L. Meng, W. Zhang, D. Li, Y. Li, X. Hu, L. Wang, G. Li, Chem. Commun. 2015, 51, 14381. [67] X. Guo, L. Wang, X. Wei, S. Zhou, J. Polym. Sci., Part A: Polym. Chem. 2016, 54, 3525. [68] C. Ke, W. Chiang, Z. Liao, H. Chen, P. Lai, J. Sun, H. Sung, Biomaterials 2013, 34, 1.\n[69] H. Chen, J. Tian, W. He, Z. Guo, J. Am. Chem. Soc. 2015, 137, 1539. [70] L. Huang, Z. Li, Y. Zhao, Y. Zhang, S. Wu, J. Zhao, G. Han, J. Am. Chem. Soc. 2016, 138, 14586. [71] L. Huang, Z. Li, Y. Zhao, J. Yang, Y. Yang, A. I. Pendharkar, Y. Zhang, S. Kelmar, L. Chen, W. Wu, J. Zhao, G. Han, Adv. Mater. 2017, 29, 1604789. [72] J. Tian, J. Zhou, Z. Shen, L. Ding, J. Yu, H. Ju, Chem. Sci. 2015, 6, 5969. [73] H. Shi, W. Sun, C. Liu, G. Gu, B. Ma, W. Si, N. Fu, Q. Zhang, W. Huang, X. Dong, J. Mater. Chem. B 2016, 4, 113. [74] P. Yuan, Z. Ruan, W. Jiang, L. Liu, J. Dou, T. Li, L. Yan, J. Mater. Chem. B 2018, 6, 2323. [75] L. Liu, L. Fu, T. Jing, Z. Ruan, L. Yan, ACS Appl. Mater. Interfaces 2016, 8, 8980. [76] S. G. Awuah, J. Polreis, V. Biradar, Y. You, Org. Lett. 2011, 13, 3884. [77] A. Bordat, T. Boissenot, J. Nicolas, N. Tsapis, Adv. Drug Delivery\nRev. 2018. [78] V. Delplace, P. Couvreur, J. Nicolas, Polym. Chem. 2014, 5, 1529. [79] Q. Chen, X. Liu, J. Zeng, Z. Cheng, Z. Liu, Biomaterials 2016, 98,\n23. [80] C. Park, K. Oh, S. C. Lee, C. Kim, Angew. Chem., Int. Ed. 2007, 46,\n1455. [81] N. K. Singh, D. S. Lee, J. Controlled Release 2014, 193, 214. [82] J. M. Brown, W. R. Wilson, Nat. Rev. Cancer 2004, 4, 437. [83] L. Liu, Z. Ruan, P. Yuan, T. Li, L. Yan, Nanotheranostics 2018, 2, 59. [84] W. Zhu, Z. Dong, T. Fu, J. Liu, Q. Chen, Y. Li, R. Zhu, L. Xu, Z. Liu,\nAdv. Funct. Mater. 2016, 26, 5490. [85] Z. Ma, X. Jia, J. Bai, Y. Ruan, C. Wang, J. Li, M. Zhang, X. Jiang,\nAdv. Funct. Mater. 2017, 27, 1604258. [86] W. Fan, W. Bu, B. Shen, Q. He, Z. Cui, Y. Liu, X. Zheng, K. Zhao,\nJ. Shi, Adv. Mater. 2015, 27, 4155. [87] Q. Peng, T. Warloe, K. Berg, J. Moan, M. Kongshaug, K. Giercksky,\nJ. M. Nesland, Cancer 1997, 79, 2282. [88] I. S. Turan, G. Gunaydin, S. Ayan, E. U. Akkaya, Nat. Commun.\n2018, 9, 805. [89] K. Pu, J. Mei, J. V. Jokerst, G. Hong, A. L. Antaris,\nN. Chattopadhyay, A. J. Shuhendler, T. Kurosawa, Y. Zhou, S. S. Gambhir, Z. Bao, J. Rao, Adv. Mater. 2015, 27, 5184. [90] L. V. Wang, S. Hu, Science 2012, 335, 1458. [91] C. J. H. Ho, G. Balasundaram, W. Driessen, R. McLaren,\nC. L. Wong, U. S. Dinish, A. B. E. Attia, V. Ntziachristos, M. Olivo, Sci. Rep. 2015, 4, 5342. [92] W. Hu, H. Ma, B. Hou, H. Zhao, Y. Ji, R. Jiang, X. Hu, X. Lu, L. Zhang, Y. Tang, Q. Fan, W. Huang, Acs Appl. Mater. Inter. 2016, 8, 12039. [93] W. Lu, Y. Lan, K. Xiao, Q. Xu, L. Qu, Q. Chen, T. Huang, J. Gao, Y. Zhao, J. Mater. Chem. B 2017, 5, 1275. [94] W. Piao, K. Hanaoka, T. Fujisawa, S. Takeuchi, T. Komatsu, T. Ueno, T. Terai, T. Tahara, T. Nagano, Y. Urano, J. Am. Chem. Soc. 2017, 139, 13713. [95] Q. Tang, W. Xiao, C. Huang, W. Si, J. Zhao, W. Huang, P. Chen, Q. Zhang, X. Dong, Chem. Mater. 2017, 29, 5216. [96] M. Zhao, Y. Xu, M. Xie, L. Zou, Z. Wang, S. Liu, Q. Zhao, Adv. Healthcare Mater. 2018, 7, 1800606. [97] Q. Tang, W. Si, C. Huang, K. Ding, W. Huang, P. Chen, Q. Zhang, X. Dong, J. Mater. Chem. B 2017, 5, 1566. [98] H. He, S. Ji, Y. He, A. Zhu, Y. Zou, Y. Deng, H. Ke, H. Yang, Y. Zhao, Z. Guo, H. Chen, Adv. Mater. 2017, 29, 1606690. [99] J. Liu, M. Li, Z. Luo, L. Dai, X. Guo, K. Cai, Nano Today 2017, 1556. [100] Q. Pei, X. Hu, X. Zheng, S. Liu, Y. Li, X. Jing, Z. Xie, ACS Nano 2018, 12, 1630. [101] A. Saneja, R. Kumar, D. Arora, S. Kumar, A. Panda, S. Jaglan, Drug Discovery Today 2018, 23, 1115.\nSmall 2019, 1804927\n1804927 (25 of 25)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\n[102] J. Xie, Z. Yang, C. Zhou, J. Zhu, R. Lee, L. Teng, Biotechnol. Adv. 2016, 34, 343. [103] B. Sun, C. Luo, W. Cui, J. Sun, Z. He, J. Controlled Release 2017, 264, 145. [104] G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, M. Gottesman, Nat. Rev. Drug Discovery 2006, 5, 219. [105] J. Liu, T. Wei, J. Zhao, Y. Huang, H. Deng, A. Kumar, C. Wang, Z. Liang, X. Ma, X. Liang, Biomaterials 2016, 91, 44. [106] J. Zhang, J. Li, Z. Shi, Y. Yang, X. Xie, S. M. Lee, Y. Wang, K. W. Leong, M. Chen, Acta Biomater. 2017, 58, 349. [107] D. Chen, Q. Tang, J. Zou, X. Yang, W. Huang, Q. Zhang, J. Shao, X. Dong, Adv. Healthcare Mater. 2018, 7, 1701272. [108] Z. Guo, Y. Zou, H. He, J. Rao, S. Ji, X. Cui, H. Ke, Y. Deng, H. Yang, C. Chen, Y. Zhao, H. Chen, Adv. Mater. 2016, 28, 10155. [109] S. Ye, J. Rao, S. Qiu, J. Zhao, H. He, Z. Yan, T. Yang, Y. Deng, H. Ke, H. Yang, Y. Zhao, Z. Guo, H. Chen, Adv. Mater. 2018, 30, 1801216. [110] M. Xiao, W. Sun, J. Fan, J. Cao, Y. Li, K. Shao, M. Li, X. Li, Y. Kang, W. Zhang, S. Long, J. Du, X. Peng, Adv. Funct. Mater. 2018, 28, 1805128. [111] H. Liu, L. Chen, C. Xu, Z. Li, H. Zhang, X. Zhang, W. Tan, Chem. Soc. Rev. 2018, 47, 7140. [112] M. P. Gamcsik, M. S. Kasibhatla, S. D. Teeter, O. M. Colvin, Biomarkers 2012, 17, 671.\nSmall 2019, 1804927"
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "Z. Dong", "L. Feng", "Y. Hao", "M. Chen", "M. Gao", "Y. Chao", "H. Zhao", "W. Zhu", "J. Liu", "C. Liang", "Q. Zhang", "Z. Liu", "J. Am" ],
      "venue" : "Soc. 2018, 140,",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2165
    }, {
      "title" : "Chem",
      "author" : [ "H. Chen", "J. Tian", "W. He", "Z. Guo", "J. Am" ],
      "venue" : "Soc. 2015, 137,",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 1539
    }, {
      "title" : "Chem",
      "author" : [ "P. Yuan", "Z. Ruan", "W. Jiang", "L. Liu", "J. Dou", "T. Li", "L. Yan", "J. Mater" ],
      "venue" : "B 2018, 6,",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2323
    }, {
      "title" : "Chem",
      "author" : [ "W. Lu", "Y. Lan", "K. Xiao", "Q. Xu", "L. Qu", "Q. Chen", "T. Huang", "J. Gao", "Y. Zhao", "J. Mater" ],
      "venue" : "B 2017, 5,",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 1275
    }, {
      "title" : "Chem",
      "author" : [ "Q. Tang", "W. Si", "C. Huang", "K. Ding", "W. Huang", "P. Chen", "Q. Zhang", "X. Dong", "J. Mater" ],
      "venue" : "B 2017, 5,",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 1566
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "[18–23] When certain PSs specifically localize in tumor sites via systemic administration and are then activated by light with a specific wavelength, a series of photochemical reactions are initiated and generate ROS to inhibit tumor growth.[22,24,25] PTT is also a commonly used type of phototherapy for cancer treatment.",
      "startOffset" : 241,
      "endOffset" : 251
    }, {
      "referenceID" : 1,
      "context" : "[67] In most cases, the core–shell structure of polymeric nanoparticles comprises a hydrophilic surface layer for stabilizing in blood circulation and a hydrophobic interior core for loading therapeutic agents including anticancer drugs or PSs.[68,69] Encapsulating BODIPY PSs with a tumor-targeting amphiphilic polymer to generate nano-photosensitizers is a promising strategy to overcome the drawbacks of self-assembly NPs and enhance photosensitizer concentration in the tumor.",
      "startOffset" : 244,
      "endOffset" : 251
    }, {
      "referenceID" : 2,
      "context" : "developed one strategy for overcoming the problem of tumor hypoxia by using self-sufficient O2-fluorinated polypeptide NPs as the carriers and the same NIR BODIPYBr2 PS (Figure 11a,b).[74] The unique electronic nature of CF bonds endowed the perfluorocarbons with excellent O2 affinity.",
      "startOffset" : 185,
      "endOffset" : 189
    }, {
      "referenceID" : 3,
      "context" : "designed core–shell Mn– 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (DBA)@BSA–PF NPs for magnetic resonance imaging (MRI) and light emitting diode (LED) light-driven water oxidation, with O2 generation attenuating hypoxia in cancer cells to achieve efficient phototherapy (Figure 18a).[93] Mn(II) is a potent T1-relaxation agent that can react with H2O2 or ROS to form a high",
      "startOffset" : 304,
      "endOffset" : 308
    }, {
      "referenceID" : 2,
      "context" : "All panels reproduced with permission.[74] Copyright 2018, The Royal Society of Chemistry.",
      "startOffset" : 38,
      "endOffset" : 42
    }, {
      "referenceID" : 4,
      "context" : "for combined PDT and PTT (Figure 21).[97] Both iodine- and bromine substituents were introduced to the BODIPY skeleton to increase the (1)O2 generation quantum yield.",
      "startOffset" : 37,
      "endOffset" : 41
    }, {
      "referenceID" : 3,
      "context" : "All panels reproduced with permission.[93] Copyright 2017, The Royal Society of Chemistry.",
      "startOffset" : 38,
      "endOffset" : 42
    }, {
      "referenceID" : 4,
      "context" : "All panels reproduced with permission.[97] Copyright 2017, The Royal Society of Chemistry.",
      "startOffset" : 38,
      "endOffset" : 42
    } ],
    "year" : 2019,
    "abstractText" : "Dr. W. Sun, X. Zhao, Prof. J. Fan, Dr. J. Du, Prof. X. Peng State Key Laboratory of Fine Chemicals Dalian University of Technology 2 Linggong Road, Hi-tech Zone, Dalian 116024, China E-mail: fanjl@dlut.edu.cn Dr. W. Sun, X. Zhao, Prof. J. Fan, Dr. J. Du, Prof. X. Peng Research Institute of Dalian University of Technology in Shenzhen Gaoxin South Fourth Road, Nanshan District, Shenzhen 518057, China The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/smll.201804927.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}